UCB SA ADR UCBJY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UCBJY is a good fit for your portfolio.
News
-
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
-
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
-
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
-
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
-
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
-
UCB on Growth Path for a Decade Plus
Trading Information
- Previous Close Price
- $67.30
- Day Range
- $66.23–66.45
- 52-Week Range
- $34.85–67.30
- Bid/Ask
- $66.01 / $66.75
- Market Cap
- $25.20 Bil
- Volume/Avg
- 30,687 / 12,496
Key Statistics
- Price/Earnings (Normalized)
- 25.75
- Price/Sales
- 4.45
- Dividend Yield (Trailing)
- 1.13%
- Dividend Yield (Forward)
- 1.12%
- Total Yield
- 1.26%
Company Profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 9,083
- Website
- https://www.ucb.com
Competitors
Valuation
|
Metric
|
UCBJY
|
EXEL
|
JAZZ
|
|---|---|---|---|
Price/Earnings (Normalized) | 25.75 | 26.13 | 5.87 |
Price/Book Value | 2.48 | 3.15 | 1.79 |
Price/Sales | 4.45 | 4.13 | 2.02 |
Price/Cash Flow | 25.52 | 21.78 | 5.97 |
Price/Earnings
UCBJY
EXEL
JAZZ
Financial Strength
|
Metric
|
UCBJY
|
EXEL
|
JAZZ
|
|---|---|---|---|
Quick Ratio | 0.84 | 3.13 | 1.52 |
Current Ratio | 1.32 | 3.34 | 2.24 |
Interest Coverage | 3.88 | — | 2.03 |
Quick Ratio
UCBJY
EXEL
JAZZ
Profitability
|
Metric
|
UCBJY
|
EXEL
|
JAZZ
|
|---|---|---|---|
Return on Assets (Normalized) | 5.10% | 9.47% | 11.62% |
Return on Equity (Normalized) | 8.82% | 11.88% | 37.73% |
Return on Invested Capital (Normalized) | 7.41% | 8.36% | 16.77% |
Return on Assets
UCBJY
EXEL
JAZZ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qgbcqwzvg | Ylhfx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lkmsywk | Zzbyk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rwsnycq | Kdfrrv | $97.8 Bil | |
MRNA
| Moderna Inc | Xwqpynkbs | Gjn | $38.8 Bil | |
ARGX
| argenx SE ADR | Kywkdmlgb | Ykqr | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Bvxpdsr | Bqp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cmfbpbjj | Rtrxz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mdhcbzkz | Xzbrgl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hqznngpq | Nwyqxcc | $12.5 Bil | |
INCY
| Incyte Corp | Hbxhjvtbb | Qczcngc | $11.5 Bil |